Immuno Cure and PharmaJet Announce Collaboration to Advance a Novel HIV Therapeutic DNA Vaccine Using Needle-Free Technology in Humans
Immuno Cure and PharmaJet have announced a collaboration to clinically evaluate ICVAX, an innovative HIV therapeutic DNA vaccine, using PharmaJet's needle-free delivery technology.
June 19, 2025
by PRNewswire
HIV and the Antiretroviral Therapy Capsid Inhibitor Lenacapavir
HIV is a major worldwide health issue, producing substantial morbidity and mortality.HIV targets the immune system, primarily CD4+ T cells, depleting them and making the body susceptible to opportunistic infections and malignancies.
January 7, 2025
by David Orchard-Webb
South Africa Ups Registration of New Pharmaceutical Products
SAHPRA has recently announced completion of a review of 16,000 applications for new products and variations nearly four years after it took over from the former regulator, the Medicines Control Council.
March 13, 2023
by SHEM OIRERE
The Last Ten Shanghai STAR Market Pharmaceutical IPOs
The last ten biopharma companies that have IPO’d on the STAR Market (Shanghai Stock Exchange Science and Technology Innovation Board) are focused on oncology, synthetic biology, genomics, HIV & pain management...
March 16, 2022
by David Orchard-Webb
Cabenuva HIV treatment approved for eight week dosing
ViiV Healthcare has announced the US Food and Drug Administration’s (FDA) approval of Cabenuva (cabotegravir, rilpivirine) in the treatment of HIV.
February 9, 2022
by EuropeanPharmaceuticalReview
Early research suggests Merck cancer drug may target dormant HIV
Antiretroviral treatments now allow many HIV patients to lead normal lives, but the drugs do not completely remove the virus from the body
January 29, 2022
by ExpressPharma
Injection of optimism as HIV vaccine trial begins
The first doses of an experimental HIV vaccine have been delivered in a phase 1 clinical trial. International AIDS Vaccine Initiative (IAVI), a non-profit scientific...
January 28, 2022
by pharmatimes
An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections
More than 1.2 million people - and potentially millions more - died in 2019 as a direct result of antibiotic-resistant bacterial infections, according to the most comprehensive estimate to date of the global impact of antimicrobial resistance (AMR).
January 24, 2022
by Pharmaceutical-Technology
Gates Foundation supports HIV and malaria research
Vir Biotech has launched a new antibody research initiative, expanding its partnership with the Bill & Melinda Gates Foundation to include the advancement of new innovations for HIV and malaria treatment.
January 15, 2022
by pharmatimes
FDA approves ViiV Healthcare’s Apretude for HIV prevention
The long-acting injectable is indicated for use in adults and adolescents who are at risk of sexually acquiring HIV and test negative for HIV-1 before initiation.
December 22, 2021
by Pharmaceutical-Business-Review
FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention
Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP)...
December 22, 2021
by FDA
First Long-Acting Injectable Approved for HIV PrEP
The U.S. Food and Drug Administration has approved the first long-acting injectable treatment for HIV preexposure prophylaxis, which is given every two months and offers an alternative to daily oral medication, the agency announced Monday.
December 21, 2021
by drugs.com